Episode
20VC: Hims & Hers: $4.3BN Market Cap on $2.3BN of Revenue: The Comeback | Why Being Public is 10x Better | The Death of the "Strategy" Hire | Why Performance Marketing is Worse than Brand Marketing with Andrew Dudum
- Published
- Apr 4, 2026
- Duration seconds
- 3558
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/twenty-minute-vc/episodes/20vc-hims-hers-4-3bn-market-cap-on-2-3bn-of-revenue-the-comeback-why-being-public-is-10x-better-the-death-of-the-strategy-hire-why-performance-marketing-is-worse-than-brand-marketing-with-andrew-dudum/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/twenty-minute-vc/20vc-hims-hers-4-3bn-market-cap-on-2-3bn-of-revenue-the-comeback-why-being-public-is-10x-better-the-death-of-the-strategy-hire-why-performance-marketing-is-worse-than-brand-marketing-with-andrew-dudum.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Andrew Dudum is the Founder and CEO of Hims, the company reshaping consumers relationship to healthcare. It has been a rocky ride over the last 6 months, the company is down 66%, their market cap today is $4.3BN on $2.3BN of revenue. They just bought their largest international competitor, Eucalyptus for $1.5BN. AGENDA: 00:00 — Why Being Public Is Better Than Private 02:50 — My Advice to The Collisons on Taking Stripe Public 07:15 — How to Hire for the Most Gritty People: The Test 10:55 — How AI Will Reshape All of Customer Acquisition 15:30 — What Did Hims Do That Andrew Wishes They Had Not Done 20:15 — What is the Least Profitable but Most Important Hims Product 27:10 — The $1.5BN Acquisition: Why Hims Bought Their Biggest Global Competitor 33:45 — Why Brand Marketing Beats Performance Marketing 39:40 — The Future of Prevention: Why Your Next Blood Test Should Be Free 46:50 — Disrupting the PBMs: How We Are Breaking the Corrupt US Healthcare System